Latest News

The Wall Street Journal: FDA approves Novavax’s COVID-19 vaccine for those 18 and older

U.S. health regulators have authorized the use of Novavax Inc.’s COVID-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand for vaccines and boosters is low.

The Food and Drug Administration said adults 18 and older may receive Novavax’s vaccine.

The Novavax
NVAX,
+0.27%

vaccine, given as two doses three weeks apart, could become available soon if the Centers for Disease Control and Prevention signs off in the coming days.

Supplies should be available soon. On Monday, the federal government agreed to secure an initial 3.2 million doses of Novavax’s vaccine pending FDA authorization. The shots will be given at no charge at pharmacies and through state and local government vaccine programs.

Demand could be limited, however. Many of the people who have wanted to get vaccinated have done so during the 19 months since vaccines were first rolled out.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

U.S. inflation hits new four-decade high of 9.1%.

Investors see far-out profits in psychedelic medicine.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

More in:Latest News

Leave a reply

Your email address will not be published. Required fields are marked *